Congestive Heart Failure Treatment Devices Market Report 2026

Congestive Heart Failure Treatment Devices Market Overview

• Congestive Heart Failure Treatment Devices market size has reached to $21.07 billion in 2025 • Expected to grow to $30.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Increasing Prevalence Of Cardiovascular Disorders Fuels Growth In Congestive Heart Failure Treatment Devices Market • Market Trend: Next-Generation Minimally Invasive Therapies For Cardiac Support • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Congestive Heart Failure Treatment Devices Market?

A congestive heart failure (CHF) treatment device is a medical device designed to aid in the management and treatment of congestive heart failure, a condition where the heart is unable to pump blood efficiently, leading to a buildup of fluid in the lungs and other tissues. These devices assist in monitoring, supporting, or improving heart function and alleviating symptoms associated with congestive heart failure by reducing symptoms, preventing complications, and decreasing the need for hospitalizations. The main product types of congestive heart failure treatment devices are cardiac pacemakers, implantable cardioverter defibrillators (ICDS), cardiac resynchronization therapy devices (CRT), counter-pulsation devices, and ventricular assist devices (VADs). A cardiac pacemaker is a small device implanted in the chest to help manage irregular heartbeats. It uses electrical pulses to prompt the heart to beat at a normal rate. The application includes left ventricular assist devices (LVAD), right ventricular assist devices (RVAD), and biventricular assist devices (BIVAD) and is used by various end-users such as hospitals and clinics, specialized cardiovascular disease treatment centers, and ambulatory surgery centers.

What Is The Congestive Heart Failure Treatment Devices Market Growth Forecast?

The congestive heart failure treatment devices market size is expected to see strong growth in the next few years. It will grow to $30.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to aging population with higher heart failure risk, increasing demand for minimally invasive cardiac therapies, growing focus on early intervention and disease management, expanding access to advanced heart failure treatment in emerging markets, rising adoption of long-term mechanical circulatory support devices. Major trends in the forecast period include rising adoption of advanced implantable heart failure devices, increasing use of ventricular assist devices in advanced chf, growing focus on reducing heart failure hospitalizations, expansion of device-based therapies for long-term heart support, increasing demand for continuous cardiac monitoring and management.

Global Congestive Heart Failure Treatment Devices Market Segmentation

1) By Product: Cardiac Pacemaker, Implantable Cardioverter Defibrillators (ICDs), Cardiac Resynchronization Therapy Devices (CRT), Counter Pulsation Devices, Ventricular Assist Devices (VADs) 2) By Application: Left Ventricular Assist Device (LVAD), Right Ventricular Assist Device (RVAD), Biventricular Assist Device (BIVAD) 3) By End-User: Hospitals And Clinic, Specialized Cardiovascular Disease Treatment Centers, Ambulatory Surgery Centers Subsegments: 1) By Cardiac Pacemaker: Single Chamber Pacemaker, Dual Chamber Pacemaker, Biventricular Pacemaker 2) By Implantable Cardioverter Defibrillators (ICDs): Traditional ICDs, Subcutaneous ICDs, CRT-D (Cardiac Resynchronization Therapy Defibrillator) 3) By Cardiac Resynchronization Therapy Devices (CRT): CRT-P (Cardiac Resynchronization Therapy Pacemaker), CRT-D (Cardiac Resynchronization Therapy Defibrillator) 4) By Counter Pulsation Devices: Intra-Aortic Balloon Pumps (IABP), External Counterpulsation Devices (ECP) 5) By Ventricular Assist Devices (VADs): Left Ventricular Assist Devices (LVAD), Right Ventricular Assist Devices (RVAD), Biventricular Assist Devices (BiVAD)

What Is The Driver Of The Congestive Heart Failure Treatment Devices Market?

The rise in the prevalence of cardiovascular disorders is expected to propel the growth of the congestive heart failure treatment devices market going forward. Cardiovascular disorders encompass a range of diseases affecting the heart and blood vessels, including coronary artery disease, hypertension, and heart failure, impacting blood circulation and overall heart health. The rise in the prevalence of cardiovascular disorders is primarily due to increasing rates of risk factors such as obesity, sedentary lifestyles, poor diets, and aging populations. Congestive heart failure treatment devices are crucial in managing cardiovascular disorders by regulating heart rhythms and improving heart function, significantly enhancing patient outcomes. For instance, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2023, cardiovascular disease claimed 919,032 lives, accounting for one in every three deaths. Coronary heart disease remained the most prevalent form of heart disease, and notably, about one in six deaths from cardiovascular diseases occurred among adults younger than 65 years. Therefore, the rise in the prevalence of cardiovascular disorders is driving the growth of the congestive heart failure (CHF) treatment devices market.

Key Players In The Global Congestive Heart Failure Treatment Devices Market

Major companies operating in the congestive heart failure treatment devices market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co KG, LivaNova PLC, Berlin Heart GmbH, Jarvik Heart Inc, ReliantHeart Inc, Abiomed Inc, Lepu Medical Technology Co Ltd, Magenta Medical Ltd, MicroPort Inc, EBR Systems Inc, Syncardia Systems LLC, Oscor Inc, OSYPKA Medical GmbH, Calon Cardio‑Technology, CoreWave SA, Zoll Medical Corporation

Global Congestive Heart Failure Treatment Devices Market Trends and Insights

Major companies operating in the congestive heart failure treatment devices market are focusing on developing innovative solutions such as the implant-free atrial septostomy system to enhance hemodynamic relief, reduce procedural complexity, and offer less invasive treatment alternatives for heart failure patients. An implant-free atrial septostomy system refers to a minimally invasive device designed to create a controlled opening in the atrial septum without leaving a permanent implant, enabling improved left atrial pressure reduction and enhanced cardiac hemodynamics in heart failure patients. For instance, in January 2025, Alleviant Medical Inc., a US-based medical device company, received significant FDA milestones for its novel no-implant interatrial shunt device for treating heart failure. It offers a minimally invasive solution for heart failure by creating a precise shunt that reduces elevated pressure in the left atrium without leaving a permanent implant. This approach minimizes complications linked to implanted devices, promotes durable shunt patency, and improves symptoms, exercise capacity, and quality of life for chronic heart failure patients. Its purpose is to unload the heart, alleviate symptoms, and provide a safer, innovative treatment option for patients with limited alternatives.

What Are Latest Mergers And Acquisitions In The Congestive Heart Failure Treatment Devices Market?

In October 2024, Johnson & Johnson, a US-based healthcare and medical technology company, completed the acquisition of V-Wave Ltd. for an undisclosed amount. Through this acquisition, Johnson & Johnson aims to strengthen its cardiovascular portfolio by integrating V-Wave’s innovative interatrial shunt technology designed to reduce left atrial pressure in patients with advanced heart failure. V-Wave Ltd. is an Israel-based medical device company, that offers congestive heart failure treatment devices.

Regional Outlook

North America was the largest region in the congestive heart failure treatment devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Congestive Heart Failure Treatment Devices Market?

The congestive heart failure treatment device market consists of sales of total artificial hearts (TAHs), external defibrillators, implantable cardioverter defibrillators, and intra-aortic balloon pumps (IABPs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.